Add to ORKGWhat are the half-lives of ranibizumab and aflibercept(VEGF Trap-eye) in humaneyes? Calculations with amathematical mode
<p>Terminal half-life of eculizumab and ALXN1210 in NOD-SCID mice in both the absence and presence o...
International audienceAIM: Aflibercept (VEGF-Trap), a novel anti-angiogenic agent that binds to VEGF...
OBJECTIVE: Although a reduced aflibercept (2.0mg) injection frequency relative to the approved dosin...
The aim of the article is to estimate the intravitreal half-lives of ranibizumab and aflibercept (VE...
Background: A drug and disease assessment model was used to evaluate the impact of different treatme...
PurposeTo compare the safety profiles of antivascular endothelial growth factor (VEGF) drugs ranibiz...
Aflibercept (Eylea®) is a recombinant fusion protein which binds to and inhibits activation of vascu...
Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degen...
PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial gr...
International audiencePURPOSE: Compare the three-year outcomes of ranibizumab versus aflibercept in ...
(A) A schematic diagram depicting the time course of our experiment. (B) The body weight gains were ...
(A) A schematic diagram depicting the time course of our experiment. (B) Whole-mounted stained retin...
Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy wi...
PURPOSE: The neovascular or wet form of age-related macular degeneration is characterized by the gro...
Intravenous zanamivir is recommended for the treatment of hospitalized patients with complicated ose...
<p>Terminal half-life of eculizumab and ALXN1210 in NOD-SCID mice in both the absence and presence o...
International audienceAIM: Aflibercept (VEGF-Trap), a novel anti-angiogenic agent that binds to VEGF...
OBJECTIVE: Although a reduced aflibercept (2.0mg) injection frequency relative to the approved dosin...
The aim of the article is to estimate the intravitreal half-lives of ranibizumab and aflibercept (VE...
Background: A drug and disease assessment model was used to evaluate the impact of different treatme...
PurposeTo compare the safety profiles of antivascular endothelial growth factor (VEGF) drugs ranibiz...
Aflibercept (Eylea®) is a recombinant fusion protein which binds to and inhibits activation of vascu...
Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degen...
PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial gr...
International audiencePURPOSE: Compare the three-year outcomes of ranibizumab versus aflibercept in ...
(A) A schematic diagram depicting the time course of our experiment. (B) The body weight gains were ...
(A) A schematic diagram depicting the time course of our experiment. (B) Whole-mounted stained retin...
Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy wi...
PURPOSE: The neovascular or wet form of age-related macular degeneration is characterized by the gro...
Intravenous zanamivir is recommended for the treatment of hospitalized patients with complicated ose...
<p>Terminal half-life of eculizumab and ALXN1210 in NOD-SCID mice in both the absence and presence o...
International audienceAIM: Aflibercept (VEGF-Trap), a novel anti-angiogenic agent that binds to VEGF...
OBJECTIVE: Although a reduced aflibercept (2.0mg) injection frequency relative to the approved dosin...